ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2010
Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers.Cancers · 2025Review
- Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective.Frontiers in immunology · 2025Article
- Identification of changes in bile composition in pancreaticobiliary reflux based on liquid chromatography/mass spectrometry metabolomics.BMC gastroenterology · 2024Article
- Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile.Current topics in medicinal chemistry · 2024Review
- Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions.Cells · 2023Review
- Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics.International journal of molecular sciences · 2023Review
- Comparative analysis of bile metabolic profile in patients with biliary obstruction complicated byFrontiers in cellular and infection microbiology · 2023Article
- Review
- Novel approaches in search for biomarkers of cholangiocarcinoma.World journal of gastroenterology · 2022Review
- Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.Frontiers in immunology · 2022Review
- Bile Processing Protocol for Improved Proteomic Analysis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Next-Generation Biomarkers for Cholangiocarcinoma.Cancers · 2021Review
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nature reviews. Gastroenterology & hepatology · 2020Review
- Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.Cancers · 2020Article
- Metabolic rearrangements in primary liver cancers: cause and consequences.Nature reviews. Gastroenterology & hepatology · 2019Review
- Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population.Hepatic medicine : evidence and research · 2019Article
- Optimizing the Method of Cell Separation from Bile of Patients with Cholangiocarcinoma for Flow Cytometry.Gastroenterology research and practice · 2019Article
- Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.Annals of translational medicine · 2018Review
- Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCholangiocarcinoma (CCA) has a poor prognosis and its aetiology is inadequately understood. Magnetic resonance spectroscopy (MRS) of bile may provide insights into the pathogenesis of CCA and help identify novel diagnostic biomarkers. The aim of this study was to compare the chemical composition of bile from patients with CCA with that of bile from patients with benign biliary disease.
methodsMagnetic resonance spectra were acquired from the bile of five CCA patients and compared with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]). Metabolic profiles were compared using both univariate and multivariate pattern-recognition analysis.
resultsUnivariate analysis showed that levels of glycine-conjugated bile acids were significantly increased in patients with CCA, compared with the benign disease groups (P= 0.002). 7 beta primary bile acids were significantly increased (P= 0.030) and biliary phosphatidylcholine (PtC) levels were reduced (P= 0.010) in bile from patients with CCA compared with bile from gallstone patients. These compounds were also of primary importance in the multivariate analysis: the cohorts were differentiated by partial least squares discriminant analysis (PLS-DA).
conclusionsThese preliminary data suggest that altered bile acid and PtC metabolism play an important role in CCA aetiopathogenesis and that specific metabolites may have potential as future biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.